On the stock market since 2017, it operates in the world of health and science. It has 162 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 52% below its peak. The market has trimmed its expectations for the company.
Sales run at $36.3M a year. A small number, but proof the product has real buyers.
The average analyst price target is $8.12 — 43% above today’s price.
A loss of $85.1M against $36.3M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, SCPH sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: SCPH is a high-risk stock — not yet profitable, and its future rides on its product catching on.